List of Excipients in Branded Drug GALANTAMINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	CELLULOSE, MICROCRYSTALLINE
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	CROSPOVIDONE
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	FERRIC OXIDE YELLOW
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	HYPROMELLOSE
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	LACTOSE MONOHYDRATE

Generic Drugs Containing GALANTAMINE

Company	Ingredient	NDC	Excipient
West-Ward Pharmaceuticals Corp	galantamine	0054-0090	ANHYDROUS LACTOSE
West-Ward Pharmaceuticals Corp	galantamine	0054-0090	CELLULOSE, MICROCRYSTALLINE
West-Ward Pharmaceuticals Corp	galantamine	0054-0090	CROSPOVIDONE
West-Ward Pharmaceuticals Corp	galantamine	0054-0090	D&C YELLOW NO. 10
West-Ward Pharmaceuticals Corp	galantamine	0054-0090	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in GALANTAMINE?

# Of NDCs	Excipient
1	AMMONIA
1	ANHYDROUS LACTOSE
14	CELLULOSE, MICROCRYSTALLINE
8	CROSPOVIDONE
1	D&C RED NO. 27

Excipient Strategy and Commercial Opportunities for Galantamine

Last updated: March 12, 2026

What is the current excipient landscape for galantamine formulations?

Galantamine is a cholinesterase inhibitor used in Alzheimer’s disease treatment. Its oral formulations typically include excipients such as microcrystalline cellulose, lactose, croscarmellose sodium, and magnesium stearate. These excipients serve as fillers, diluents, disintegrants, and lubricants.

Existing formulations are primarily immediate-release tablets. Liquid formulations incorporate excipients like glycerol, propylene glycol, and benzyl alcohol. These excipients must ensure drug stability, bioavailability, and patient acceptability.

How do excipient choices impact drug bioavailability and stability?

Excipient selection influences galantamine's solubility, disintegration, and absorption. Disintegrants like croscarmellose sodium facilitate rapid tablet disintegration, improving onset. Fillers such as microcrystalline cellulose provide structural integrity.

Stability concerns include excipient interactions that influence shelf life. Lactose, for example, may cause issues in non-microbially stable products due to hygroscopicity. Antioxidants like ascorbic acid are sometimes added to prevent oxidation.

What are innovation opportunities in excipient development?

New excipients can enhance delivery and patient compliance. Potential strategies include:

• Modified-release excipients: Use of hydrophilic matrices or osmotic systems to sustain drug release, reducing dosing frequency.
• Mucoadhesive excipients: Incorporation of chitosan or polycarbophil to improve bioavailability through mucosal adhesion.
• Taste-masking agents: For pediatric or geriatric formulations, applying taste-neutral excipients to improve palatability.
• Nanostructured excipients: Lipid or polysaccharide-based systems to enhance solubility and absorption.

What are the commercial opportunities linked to excipient innovation?

Innovative excipient strategies can differentiate products through improved efficacy, stability, and patient adherence. These advantages can command premium pricing and facilitate regulatory approvals.

Market expansion potential includes:

• Generic markets: Reformulating existing galantamine products with improved excipients to extend patent life or sell as new formulations.
• Over-the-counter (OTC) products: Developing formulations with better taste and ease of administration aimed at early intervention markets.
• Combination therapies: Pairing galantamine with other agents in controlled-release delivery systems.

Market data indicates that the global Alzheimer’s drug market is projected to reach USD 13.37 billion by 2027, growing at a CAGR of 8.9% (Fortune Business Insights, 2022). Excipients that enable novel formulations can access this expanding market space.

How are regulatory pathways affected by excipient choices?

Regulatory bodies, such as the FDA and EMA, require in-depth characterization of excipients. Novel excipients or new uses demand comprehensive safety data and stability testing.

For reformulated products, abbreviated pathways like 505(b)(2) submissions in the U.S. assess excipient changes’ impact. Demonstrating equivalence or improved performance can streamline approval processes.

Key considerations for formulation development and commercialization

• Compatibility: Assess excipient-drug interactions via stability studies.
• Patient-centric design: Incorporate excipients that improve taste, swallowability, and dosing convenience.
• Scale-up and cost: Balance innovative excipients with manufacturing feasibility and cost-effectiveness.
• Regulatory compliance: Ensure excipient sourcing, safety data, and documentation meet regional requirements.

Final thoughts

Developing an excipient strategy around galantamine involves balancing stability, bioavailability, patient compliance, and regulatory considerations. Innovation in excipient formulations can unlock new market segments and enhance product differentiation.

---

Key Takeaways

• Excipient selection for galantamine impacts stability, bioavailability, and patient adherence.
• Opportunities exist in sustained-release, mucoadhesive, taste-masked, and nanostructured excipients.
• Innovation can support market expansion through reformulation and combination therapies.
• Regulatory pathways favor well-characterized and safe excipients; novel excipients require robust data.
• Market growth driven by Alzheimer’s prevalence incentivizes investment in advanced galantamine formulations.

---

FAQs

1. What excipients are most commonly used in galantamine tablets?
Microcrystalline cellulose, lactose, croscarmellose sodium, and magnesium stearate.

2. Can new excipients improve galantamine’s bioavailability?
Yes; mucoadhesive and nanostructured excipients can enhance absorption.

3. Are there regulatory hurdles for innovative excipients?
Yes; novel excipients require safety data and regulatory review, but reformulation using approved excipients faces fewer barriers.

4. How does excipient choice affect patient compliance?
Excipients that improve taste, reduce pill size, or enable controlled release enhance adherence.

5. What market opportunities exist for improved galantamine formulations?
Premium-priced formulations, OTC products, and combination therapies leverage excipient innovations for growth.

---

References

[1] Fortune Business Insights. (2022). Alzheimer’s Disease Therapeutics Market Size, Share & Industry Analysis.
[2] U.S. Food and Drug Administration. (2020). Guidance for Industry — Orally Inhaled Drug Products.